Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

L. Sokol, L. Cripe, H. Kantarjian, M. A. Sekeres, S. Parmar, P. Greenberg, S. L. Goldberg, V. Bhushan, J. Shammo, R. Hohl, A. Verma, G. Garcia-Manero, Y. P. Li, A. Lowe, J. Zhu, A. F. List

Research output: Contribution to journalLetter

21 Scopus citations
Original languageEnglish (US)
Pages (from-to)977-980
Number of pages4
JournalLeukemia
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., Goldberg, S. L., Bhushan, V., Shammo, J., Hohl, R., Verma, A., Garcia-Manero, G., Li, Y. P., Lowe, A., Zhu, J., & List, A. F. (2013). Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia, 27(4), 977-980. https://doi.org/10.1038/leu.2012.264